HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stern, Y. Articles by Langston, J. W. Search for Related Content PubMed PubMed Citation Articles by Stern, Y. Articles by Langston, J. W.

Intellectual changes in patients with MPTP-induced parkinsonism

From the Department of Neurology (Dr. Stern), Columbia hiversity, College of Physicians and Surgeons, and the Department of Neurology (Dr. Langston), Santa Clara Valley Medical Center and Stanford University School of Medicine.

We studied six patients with MPTP-induced parkinsonism to assess intellectual function, attention, reaction time, and depression. Eight controls with a similar history of drug abuse also participated. General intellectual function, construction, category naming, and frontal lobe function were worse in the patients; other aspects of performance were comparable. All affected women but none of the men were depressed, usually before onset of parkinsonism. The pattern of intellectual deficit in the MPTP patients was similar to that of idiopathic Parkinson's disease. Since MPTP-induced parkinsonism probably represents a purely dopaminergic deficiency, these findings suggest that changes in the dopamine system are responsible for at least some of the intellectual changes CS idiopathic Parkinson's disease.

Address correspondence and reprint requests to Dr. Stern, Neurological Institute, 710 West 168th Street, New York, NY 10032.

Supported in part by a federal grant (R01 AG02802–04) and by the Parkinson's Disease Fnundation, New York (Dr. Stern), and the Retirement Research Foundatiun, Park Ridge, IL (Dr. LanKston).

Presented in part at the annual meeting of the American Neurological Association, Baltimore, MD, October 1984.

Accepted for publication January 14, 1985.

This article has been cited by other articles:

				A. Abi-Dargham and H. Moore Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia Neuroscientist, October 1, 2003; 9(5): 404 - 416. [Abstract] [PDF]

				J. Shumake and F. Gonzalez-Lima Brain Systems Underlying Susceptibility to Helplessness and Depression Behav Cogn Neurosci Rev, September 1, 2003; 2(3): 198 - 221. [Abstract] [PDF]

				J. O. Rinne, R. Portin, H. Ruottinen, E. Nurmi, J. Bergman, M. Haaparanta, and O. Solin Cognitive Impairment and the Brain Dopaminergic System in Parkinson Disease: [18F]Fluorodopa Positron Emission Tomographic Study Arch Neurol, April 1, 2000; 57(4): 470 - 475. [Abstract] [Full Text] [PDF]

				H. Slovin, M. Abeles, E. Vaadia, I. Haalman, Y. Prut, and H. Bergman Frontal Cognitive Impairments and Saccadic Deficits in Low-Dose MPTP-Treated Monkeys J Neurophysiol, February 1, 1999; 81(2): 858 - 874. [Abstract] [Full Text] [PDF]

				D. P. Roeltgen and J. S. Schneider Chronic Low-Dose MPTP in Nonhuman Primates: A Possible Model for Attention Deficit Disorder J Child Neurol, January 1, 1991; 6(1_suppl): S82 - S89. [Abstract] [PDF]

				W. W. Beatty, R. D. Staton, W. S. Weir, N. Monson, and H. A. Whitaker Cognitive Disturbances in Parkinson's Disease J Geriatr Psychiatry Neurol, January 1, 1989; 2(1): 22 - 33. [Abstract] [PDF]

				J. L. Cummings Intellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates J Geriatr Psychiatry Neurol, January 1, 1988; 1(1): 24 - 36. [Abstract] [PDF]

				R Lewin Clinical trial for Parkinson's disease? Science, November 1, 1985; 230(4725): 527 - 528. [PDF]